NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics

[unable to retrieve full-text content]PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the upcoming presentation of data from spinoff company Curadigm at the 2020 Virtual Meeting of the American Association for Cancer Research (AACR) . The results demonstrate that Curadigm’s novel “Nanoprimer” technology can improve the efficacy of thera

About the Author: Biotech Today

You might like